sulfasalazine has been researched along with Carcinoma, Hepatocellular in 8 studies
Sulfasalazine: A drug that is used in the management of inflammatory bowel diseases. Its activity is generally considered to lie in its metabolic breakdown product, 5-aminosalicylic acid (see MESALAMINE) released in the colon. (From Martindale, The Extra Pharmacopoeia, 30th ed, p907)
sulfasalazine : An azobenzene consisting of diphenyldiazene having a carboxy substituent at the 4-position, a hydroxy substituent at the 3-position and a 2-pyridylaminosulphonyl substituent at the 4'-position.
Carcinoma, Hepatocellular: A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The aims of the present study were to assess: (i) expression status of CD44v9 and xCT in hepatocellular carcinoma (HCC) tissues, including those derived from patients treated with hepatic arterial infusion chemoembolization (HAIC) therapy with cisplatin (CDDP); and (ii) whether combination of CDDP with sulfasalazine (SASP), an inhibitor of xCT, was more effective on tumor cells than CDDP alone by inducing ROS-mediated apoptosis." | 7.88 | High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine. ( Abe, M; Akiba, J; Ikezono, Y; Iwamoto, H; Kakuma, T; Koga, H; Masuda, A; Nakamura, T; Niizeki, T; Sakaue, T; Tanaka, T; Torimura, T; Wada, F; Yano, H, 2018) |
| "Malignant ascites in advanced hepatocellular carcinoma (HCC) is a complex clinical problem that lacks effective treatments." | 5.91 | Ferroptosis-Enhanced Immunotherapy with an Injectable Dextran-Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma. ( Deng, S; Deng, Y; Hu, Y; Huang, J; Jin, H; Liao, Z; Liu, Y; Lovell, JF; Meng, J; Tian, Y; Tuo, Z; Yang, K; Yang, X; Zhou, Z, 2023) |
| "CD133-positive cells in hepatocellular carcinoma (HCC) exhibit cancer stem cell (CSC)-like properties as well as resistance to chemotherapeutic agents and ionizing radiation; however, their function remains unknown." | 5.46 | Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells. ( Bae, SM; Choi, EK; Jang, J; Kim, JS; Kim, KM; Myung, SJ; Seo, HR; Shin, TH; Song, Y, 2017) |
| " The aims of the present study were to assess: (i) expression status of CD44v9 and xCT in hepatocellular carcinoma (HCC) tissues, including those derived from patients treated with hepatic arterial infusion chemoembolization (HAIC) therapy with cisplatin (CDDP); and (ii) whether combination of CDDP with sulfasalazine (SASP), an inhibitor of xCT, was more effective on tumor cells than CDDP alone by inducing ROS-mediated apoptosis." | 3.88 | High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine. ( Abe, M; Akiba, J; Ikezono, Y; Iwamoto, H; Kakuma, T; Koga, H; Masuda, A; Nakamura, T; Niizeki, T; Sakaue, T; Tanaka, T; Torimura, T; Wada, F; Yano, H, 2018) |
| "Malignant ascites in advanced hepatocellular carcinoma (HCC) is a complex clinical problem that lacks effective treatments." | 1.91 | Ferroptosis-Enhanced Immunotherapy with an Injectable Dextran-Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma. ( Deng, S; Deng, Y; Hu, Y; Huang, J; Jin, H; Liao, Z; Liu, Y; Lovell, JF; Meng, J; Tian, Y; Tuo, Z; Yang, K; Yang, X; Zhou, Z, 2023) |
| "CD133-positive cells in hepatocellular carcinoma (HCC) exhibit cancer stem cell (CSC)-like properties as well as resistance to chemotherapeutic agents and ionizing radiation; however, their function remains unknown." | 1.46 | Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells. ( Bae, SM; Choi, EK; Jang, J; Kim, JS; Kim, KM; Myung, SJ; Seo, HR; Shin, TH; Song, Y, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 4 (50.00) | 24.3611 |
| 2020's | 3 (37.50) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, S | 1 |
| Zhang, L | 1 |
| Chen, Y | 1 |
| Fu, L | 1 |
| Meng, J | 1 |
| Yang, X | 1 |
| Huang, J | 1 |
| Tuo, Z | 1 |
| Hu, Y | 1 |
| Liao, Z | 1 |
| Tian, Y | 1 |
| Deng, S | 1 |
| Deng, Y | 1 |
| Zhou, Z | 1 |
| Lovell, JF | 1 |
| Jin, H | 1 |
| Liu, Y | 1 |
| Yang, K | 1 |
| Shamaa, MM | 1 |
| Wada, F | 1 |
| Koga, H | 1 |
| Akiba, J | 1 |
| Niizeki, T | 1 |
| Iwamoto, H | 1 |
| Ikezono, Y | 1 |
| Nakamura, T | 1 |
| Abe, M | 1 |
| Masuda, A | 1 |
| Sakaue, T | 1 |
| Tanaka, T | 1 |
| Kakuma, T | 1 |
| Yano, H | 1 |
| Torimura, T | 1 |
| Anwar, DM | 1 |
| Khattab, SN | 1 |
| Helmy, MW | 1 |
| Kamal, MK | 1 |
| Bekhit, AA | 1 |
| Elkhodairy, KA | 1 |
| Elzoghby, AO | 1 |
| Song, Y | 1 |
| Jang, J | 1 |
| Shin, TH | 1 |
| Bae, SM | 1 |
| Kim, JS | 1 |
| Kim, KM | 1 |
| Myung, SJ | 1 |
| Choi, EK | 1 |
| Seo, HR | 1 |
| Guo, W | 1 |
| Zhao, Y | 1 |
| Zhang, Z | 1 |
| Tan, N | 1 |
| Zhao, F | 1 |
| Ge, C | 1 |
| Liang, L | 1 |
| Jia, D | 1 |
| Chen, T | 1 |
| Yao, M | 1 |
| Li, J | 1 |
| He, X | 1 |
| Izumiya, M | 1 |
| Yajima, T | 1 |
| Serizawa, H | 1 |
| Watanabe, N | 1 |
| Hamada, Y | 1 |
| Tsunematsu, S | 1 |
| Kumagai, N | 1 |
| Tsuchimoto, K | 1 |
| Toyoda, H | 1 |
| Hibi, T | 1 |
| Ishii, H | 1 |
2 reviews available for sulfasalazine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Inhibiting Sodium Taurocholate Cotransporting Polypeptide in HBV-Related Diseases: From Biological Function to Therapeutic Potential.
Topics: Carcinoma, Hepatocellular; Hep G2 Cells; Hepatitis B; Hepatitis B virus; Hepatocytes; Humans; Interf | 2022 |
[A case of Crohn's disease complicated with hepatocellular carcinoma].
Topics: Adult; Anti-Inflammatory Agents; Carcinoma, Hepatocellular; Crohn Disease; Drug Combinations; Drug T | 2003 |
6 other studies available for sulfasalazine and Carcinoma, Hepatocellular
| Article | Year |
|---|---|
Ferroptosis-Enhanced Immunotherapy with an Injectable Dextran-Chitosan Hydrogel for the Treatment of Malignant Ascites in Hepatocellular Carcinoma.
Topics: Ascites; Carcinoma, Hepatocellular; Chitosan; Dextrans; Ferroptosis; Humans; Hydrogels; Immunotherap | 2023 |
Sulfasalazine synergistically enhances the inhibitory effects of imatinib against hepatocellular carcinoma (HCC) cells by targeting NFκB, BCR/ABL, and PI3K/AKT signaling pathway-related proteins.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Synergism; Gene | 2021 |
High expression of CD44v9 and xCT in chemoresistant hepatocellular carcinoma: Potential targets by sulfasalazine.
Topics: Aged; Aged, 80 and over; Amino Acid Transport System y+; Animals; Apoptosis; Carcinoma, Hepatocellul | 2018 |
Lactobionic/Folate Dual-Targeted Amphiphilic Maltodextrin-Based Micelles for Targeted Codelivery of Sulfasalazine and Resveratrol to Hepatocellular Carcinoma.
Topics: Animals; Antineoplastic Agents; Carcinoma, Hepatocellular; Disaccharides; Drug Delivery Systems; Fol | 2018 |
Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells.
Topics: AC133 Antigen; Animals; Carcinoma, Hepatocellular; Cell Culture Techniques; Cell Line, Tumor; Drug R | 2017 |
Disruption of xCT inhibits cell growth via the ROS/autophagy pathway in hepatocellular carcinoma.
Topics: Amino Acid Transport System y+; Animals; Autophagy; Carcinoma, Hepatocellular; Cell Growth Processes | 2011 |